New HPLC method identifies four impurities in brimonidine tartrate, suggesting quality control improvements.
The four impurities in Brimonidine Tartrate bulk drug substances were detected by newly developed gradient reverse phase high performance liquid chromatography (HPLC) method. These impurities were named as Brimonidine Impurity- A, B, C, and D. The Brimonidine Impurity-A, Brimonidine Impurity-B, Brimonidine Impurity-C were process impurities, while Brimonidine Impurity-D is degradation impurity. The degradation Brimonidine Impurity-D was isolated by semi preparative HPLC. Structural elucidation of unknown impurities was carried out by means of (conformed by) spectral studies like IR, NMR and Mass synthesized authentic compounds.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: